A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs

NCT05663515 · clinicaltrials.gov ↗

RECRUITING

Status

24000

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreatic Cancer

Interventions

DRUG: Exenatide
DRUG: Non-GLP-1 RA based glucose lowering drugs

Sponsor

AstraZeneca

Collaborators

[object Object]